Suven Life Sciences Ltd has obtained two products patents, one each from Europe and Macau, for its New Chemical Entities (NCEs) for the treatment of neurodegenerative diseases.
The granted claims of the patents include the class of selective alpha 4-beta 2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder, the Hyderabad-based company said in a release issued here on Tuesday.
Suven Life Sciences’ scrip gained 3.84 per cent after opening of trade on the Bombay Stock Exchange on Tuesday and is trading at Rs 272.